BFA
ACHN

BlackRock Fund Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

BlackRock Fund Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$22.3M Buy
5,411,414
+626,133
+13% +$3.33M ﹤0.01% 2118
2016
Q3 		$38.8M Buy
4,785,281
+254,100
+6% +$2.16M 0.01% 1746
2016
Q2 		$35.3M Sell
4,531,181
-42,132
-0.9% -$361K 0.01% 1716
2016
Q1 		$35.3M Buy
4,573,313
+102,179
+2% +$748K 0.01% 1659
2015
Q4 		$48.2M Sell
4,471,134
-252,325
-5% -$2.29M 0.01% 1492
2015
Q3 		$32.6M Buy
4,723,459
+390,846
+9% +$3.18M 0.01% 1699
2015
Q2 		$38.4M Sell
4,332,613
-205,121
-5% -$1.94M 0.01% 1699
2015
Q1 		$44.7M Buy
4,537,734
+686,480
+18% +$8.57M 0.01% 1571
2014
Q4 		$47.2M Buy
3,851,254
+366,133
+11% +$4.47M 0.01% 1506
2014
Q3 		$34.8M Sell
3,485,121
-66,791
-2% -$620K 0.01% 1594
2014
Q2 		$26.9M Sell
3,551,912
-68,187
-2% -$272K 0.01% 1832
2014
Q1 		$11.9M Buy
3,620,099
+145,717
+4% +$510K ﹤0.01% 2297
2013
Q4 		$11.5M Sell
3,474,382
-71,323
-2% -$207K ﹤0.01% 2307
2013
Q3 		$10.7M Buy
3,545,705
+467,270
+15% +$3.2M ﹤0.01% 2319
2013
Q2 		$25.2M Buy
+3,078,435
New +$23.5M 0.01% 1681

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock Fund Advisors's ACHN Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Achillion Pharmaceuticals (ACHN) stake by 13% in Q4 2016, buying an estimated $3.33M and bringing the position to 5,411,414 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2118.

BlackRock Fund Advisors first reported a position in ACHN in Q2 2013 and has held it in 15 quarters since. The position peaked at $48.2M in Q4 2015. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • BlackRock Fund Advisors held 5,411,414 shares of Achillion Pharmaceuticals worth $22.3M as of Q4 2016.
  • BlackRock Fund Advisors bought 626,133 Achillion Pharmaceuticals shares in Q4 2016, an estimated $3.33M.
  • Achillion Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2118 holding.
  • BlackRock Fund Advisors first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Achillion Pharmaceuticals position peaked at $48.2M in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.